Connor, Clark & Lunn Investment Management (CC&L)’s 10x Genomics TXG Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19.9M	Buy	938,408 +228,829	+32%	+$4.57M	0.05%	317
2025 Q4	$11.6M	Buy	709,579 +392,106	+124%	+$5.92M	0.03%	426
2025 Q3	$3.71M	Buy	+317,473	New	+$4.14M	0.01%	666
2023 Q1	–	Sell	-25,085	Closed	-$914K	–	1461
2022 Q4	$914K	Buy	+25,085	New	+$820K	0.01%	728

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s TXG Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its 10x Genomics (TXG) stake by 32% in Q1 2026, buying an estimated $4.57M and bringing the position to 938,408 shares worth $19.9M. The position accounts for 0.05% of the portfolio, ranked #317.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in TXG in Q4 2022 and has held it in 4 quarters since. 330 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 938,408 shares of 10x Genomics worth $19.9M as of Q1 2026.
Connor, Clark & Lunn Investment Management (CC&L) bought 228,829 10x Genomics shares in Q1 2026, an estimated $4.57M.
10x Genomics made up 0.05% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #317 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in 10x Genomics in Q4 2022 and has held it in 4 quarters since.
330 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.